Johnson & Johnson (JNJ) Assets Average (2009 - 2026)
Johnson & Johnson (JNJ) posted Assets Average of $201.0 billion for Q2 2026, little changed sequentially from $200.1 billion in Q1 2026, and up 3.85% YoY from $193.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Assets Average (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Assets Average for 18 years, with the latest figure at $201.0 billion in Q2 2026.
- Quarterly Assets Average rose 3.85% year-over-year to $201.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $201.0 billion (up 3.85% YoY) and the FY2025 annual result came in at $189.7 billion, up 9.1% from the prior year.
- Assets Average steadied at $201.0 billion in Q2 2026 per JNJ's latest filing, from $200.1 billion in the prior quarter.
- Over five years, Assets Average peaked at $201.0 billion in Q2 2026 and troughed at $166.8 billion in Q4 2023.
- A 5-year average of $184.4 billion and a median of $180.6 billion in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average retreated 11.43% in 2024, then climbed 10.09% in 2025.
- Over 5 years, Assets Average stood at $176.4 billion in 2022, then decreased by 5.45% to $166.8 billion in 2023, then rose by 7.43% to $179.2 billion in 2024, then advanced by 9.39% to $196.0 billion in 2025, then advanced by 2.53% to $201.0 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $201.0 billion, $200.1 billion, and $196.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.77 Bn | 633.01 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 470.28 Bn | 463.71 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 377.51 Bn | 370.37 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.01 Bn | 253.11 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 236.60 Bn | 222.61 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 183.35 Bn | 180.17 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 160.34 Bn | 148.64 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 55.31 Bn | 47.93 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 200.98 Bn |
| Mar 29, 2026 | 200.05 Bn |
| Dec 28, 2025 | 196.01 Bn |
| Sep 28, 2025 | 193.10 Bn |
| Jun 29, 2025 | 193.53 Bn |
| Mar 30, 2025 | 186.89 Bn |
| Dec 29, 2024 | 179.20 Bn |
| Sep 29, 2024 | 179.69 Bn |
| Jun 30, 2024 | 176.53 Bn |
| Mar 31, 2024 | 169.76 Bn |
| Dec 31, 2023 | 166.81 Bn |
| Oct 1, 2023 | 178.87 Bn |
| Jul 2, 2023 | 193.83 Bn |
| Apr 2, 2023 | 191.67 Bn |
| Jan 1, 2023 | 181.25 Bn |
| Oct 2, 2022 | 176.42 Bn |
| Jul 3, 2022 | 178.04 Bn |
| Apr 3, 2022 | 180.19 Bn |
| Jan 2, 2022 | 180.62 Bn |
| Oct 3, 2021 | 177.83 Bn |